CD20 has been targeted in MCL with anti-CD20 antibodies (Rituximab), which causes death of tumor cells through several mechanisms including anti-proliferative effects and pro-apoptotic effects in B cells [46]. Here, MS4A1 is linked to mantle cell lymphoma.